Perspective Therapeutics (CATX) Other Operating Expenses (2010 - 2024)
Perspective Therapeutics' (CATX) quarterly Other Operating Expenses came in at $32000.0 in Q4 2024, up 45.45% year-over-year from $22000.0 in Q1 2024, and up 152.46% quarter-over-quarter from -$61000.0 in Q2 2024.
Analysis
Perspective Therapeutics (CATX) Other Operating Expenses (2010 - 2024) Analysis & Trends
Perspective Therapeutics has disclosed Other Operating Expenses across 15 years of filings, most recently posting $32000.0 for Q4 2024.
- In Q4 2024, Other Operating Expenses rose 45.45% year-over-year to $32000.0; the TTM figure through Mar 2026 stood at $32000.0 (up 210.34% YoY), while the FY2024 annual figure was -$27000.0, changed N/A from the prior year.
- Other Operating Expenses came in at $32000.0 for Q4 2024 at Perspective Therapeutics, up from -$61000.0 in the prior quarter.
- In the past five years, Other Operating Expenses ranged from a high of $1.3 million in Q2 2022 to a low of -$305000.0 in Q4 2022.
- Average Other Operating Expenses over 5 years is $219000.0, with a median of $27000.0 recorded in 2023.
- The largest YoY upside for Other Operating Expenses was 29300.0% in 2020 against a maximum downside of 102.53% in 2020.
- Over 5 years, Other Operating Expenses stood at -$7000.0 in 2020, then soared by 10128.57% to $702000.0 in 2021, then sank by 143.45% to -$305000.0 in 2022, then soared by 107.21% to $22000.0 in 2023, then surged by 45.45% to $32000.0 in 2024.
- Per Business Quant data, the three most recent Other Operating Expenses figures were $32000.0 in Q4 2024, -$61000.0 in Q2 2024, and $22000.0 in Q4 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn |
| 10 | Perspective Therapeutics | 361.95 Mn | 361.95 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | 32,000.00 |
| Jun 30, 2024 | -61,000.00 |
| Dec 31, 2023 | 22,000.00 |
| Mar 31, 2023 | -22,000.00 |
| Dec 31, 2022 | -305,000.00 |
| Jun 30, 2022 | 1.34 Mn |
| Sep 30, 2021 | 702,000.00 |
| Mar 31, 2021 | -2,000.00 |
| Dec 31, 2020 | -7,000.00 |
| Sep 30, 2020 | 312,000.00 |
| Jun 30, 2020 | 322,000.00 |
| Mar 31, 2020 | 294,000.00 |
| Dec 31, 2019 | 277,000.00 |
| Sep 30, 2019 | 160,000.00 |
| Mar 31, 2019 | 1,000.00 |
| Dec 31, 2018 | 23,000.00 |
| Sep 30, 2018 | 420,000.00 |
| Jun 30, 2018 | 572,000.00 |
| Mar 31, 2018 | 473,000.00 |
| Dec 31, 2017 | 340,000.00 |